Orbit Discovery and Evergreen Discovery Collaborate To Discover Peptides for Targeting Radiopharmaceuticals
Complete the form below to unlock access to ALL audio articles.
Evergreen Discovery (Evergreen) and Orbit Discovery Ltd (Orbit) have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities ranging from designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties.
The radiopharmaceuticals market is rapidly expanding with the development of a variety of targeting moieties. These moieties allow for specific binding to a tumour target of interest, thereby localising the treatment to diseased tissues. Peptides are increasingly seen as a valuable delivery option, as their specificity, stability and rapid clearance has the potential to reduce off-target toxicities.
The collaboration will leverage Orbit’s peptide display technologies to find peptide leads specific to tumour related targets of interest. The proprietary platform will harness its unique ability to perform in vitro transcription translation from DNA-encoded libraries on beads. This capability allows for screening of huge libraries using Fluorescence-activated cell sorting (FACS)-based methodologies, thereby significantly increasing throughput above other competing technologies. Evergreen will focus on subsequent development of the peptides for clinical use.
Dr Thomas Reiner, Chief Scientific Officer, Evergreen Discovery, commented: “We are very pleased to be partnering with Orbit Discovery and capitalising on its technology and expertise in both chemistry and biology to drive innovation and expansion of our radiopharmaceutical candidate pipeline.” He added: “The requirement for more direct screening technologies is key to successful drug development and we see Orbit as a steppingstone in attaining our goals in a rapid timeframe.”
Dr Neil Butt, Chief Executive Officer, Orbit Discovery, said: “Evergreen Discovery is a pioneer in the field of radiopharmaceuticals, and we’re delighted to be collaborating with the team. In conjunction with their capabilities in manufacturing, we aim to assist them in rapidly moving targeted radiopharmaceuticals into the clinic.” He added: “This area of therapeutic drug development benefits significantly from our platform, where the higher numbers screened typically allow for better outputs and thereby reduce risk at a later stage in development.”